【摘要】目的：比较诺和锐30和诺和灵30R每日2次皮下注射治疗在开始胰岛素治疗的2型糖尿病(T2DM)患者的疗效和安全性。方法：为期12周的随机、开放性比较研究。72例T2DM患者被随机分为诺和锐30治疗组和诺和灵30R治疗组，采用每日早、晚餐前两次皮下注射方案，观察两组患者7个时点血糖、糖化血红蛋白(HbA1c)、低血糖事件及其他不良事件的差异。结果:诺和锐30治疗组三餐后血糖水平明显低于诺和灵30R治疗组(P<0.05)；诺和锐30组低血糖发生次数低于诺和灵30R组，严重低血糖发生次数约为诺和灵30R组的二分之一；两组HbA1c、胰岛素用量及其他不良事件差异无统计学意义。结论：T2DM患者采用早、晚餐前预混胰岛素皮下注射方案治疗时，诺和锐30对餐后血糖控制更为满意，且低血糖事件发生率少；两种治疗之间的总体血糖控制水平相似。

    【关键词】诺和锐30 诺和灵30R 2型糖尿病 胰岛素 低血糖

    Comparison of BIAsp30 and BHI30 in patients with type 2 diabetes mellitus who begin to use insulin

    BIAN Wei.Jinan Fourth People's Hospital，Shandong 250031，China

    【Abstract】 ObjectiveTo compare the curative effect and security of BIAsp30 and BHI30 in patients with type 2 diabetes mellitus(T2DM)who begin to use insulin.MethodsA 12-w open and random study was performed.All 72 patients with T2DM were randomly divided into 2 groups.One group was treated by BIAsp30 and the other by BHI30.Both drugs were respectively injected subcutaneously to the patients.Blood glucose at 7 time points,glycosylated hemoglobin and hypoglycemia were observed.ResultsThe postprandial blood glucose was significantly lower in BIAsp30 group than in BHI30 one(P<0.05),and the frequency of hypoglycemia was lower in BIAsp30 group than in the other one . There was no difference between glycosylated hemoglobin and dosage of insulin.ConclusionBIAsp30 is superior to BHI30,not only in controlling the postprandial blood glucose but also in reducing the incidence of hypoglycemia,and the total blood glucose control shows similar in both treatments. ......